Litcius/Paper detail

Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC

Prerna Arora, Christine Happle, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Alexandra Dopfer‐Jablonka, Georg M. N. Behrens, Stefan Pöhlmann, Markus Hoffmann

2024The Lancet Infectious Diseases45 citationsDOIOpen Access PDF

Topics & Concepts

Booster (rocketry)NeutralizationVirologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VaccinationCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakPandemicMedicineOutbreakInfectious disease (medical specialty)EngineeringVirusAerospace engineeringDiseasePathologySARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies
Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC | Litcius